This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Commentary by Roger N. Rosenberg, MD

JAMA. 2002;288(23):3045-3047.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF NEUROLOGY

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

M. Riemenschneider, MD; N. Lautenschlager, MD; S. Wagenpfeil, PhD; J. Diehl, MD; A. Drzezga, MD; A. Kurz, MD

Context  Cerebrospinal fluid tau protein and β-amyloid 42 (Aβ42) protein are altered even in very mild Alzheimer disease (AD). So far, few data exist for subjects with mild cognitive impairment (MCI).

Objective  To investigate the potential of cerebrospinal fluid tau and Aβ42 for predicting progression from MCI to AD in a longitudinal study of 28 patients with MCI who received follow-up for 18 months.

Design  An 18-month prospective study.

Setting  Clinical follow-up study of community-residing subjects with MCI.

Main Outcome Measures  Cerebrospinal fluid tau and Aβ42 concentrations were measured using enzyme-linked immunosorbent assay at baseline. The potential ofboth biomarkers was evaluated to predict the progression to dementia, . . . [Full Text of this Article]